IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab plus Carboplatin plus Etoposide in Extensive-Stage SCLC-MedSci.cn

IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab plus Carboplatin plus Etoposide in Extensive-Stage SCLC

Liu, S; Mansfield, A; Szczesna, A; Havel, L; Krzakowski, M; Hochmair, M; Huemer, F; Losonczy, G; Johnson, M; Nishio, M; Reck, M; Mok, T; Lam, S; Shames, D; Liu, J; Ding, B; Kabbinavar, F; Lin, W; Sandler, A; Horn, L

JOURNAL OF THORACIC ONCOLOGY, 2018; 13 (10): S185

科室
- - 订阅+
  - 更多科室
工具
服务